+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Percutaneous estradiol gel with an intrauterine levonorgestrel releasing device or natural progesterone in hormone replacement therapy



Percutaneous estradiol gel with an intrauterine levonorgestrel releasing device or natural progesterone in hormone replacement therapy



Maturitas. 26(3): 211-217



Objective: To evaluate the bleeding patterns and clinical compliance associated with postmenopausal amenorrhea-inducing forms of hormone replacement therapy using either percutaneous estradiol-gel and a levonorgestrel-releasing intrauterine device or an oral/vaginal natural progesterone. Methods: Sixty postmenopausal women with an intact uterus were followed over 12 months in this open, non-randomized, parallel group study. All patients continuously received a gel containing 1.5 mg of estradiol daily. The women were divided into three groups on the basis of progestin administration. Twenty women (group I) had a levonorgestrel-releasing device (LNG-IUD) inserted at the beginning of the study. Twenty-one women (group II) received oral natural micronised progesterone (oral P) 100 mg daily during 25 calendar days each month, and 19 women (group III) used vaginal natural micronised progesterone (vaginal P) 100-200 mg daily during 25 calendar days each month (higher dose if spotting occurred). Clinic visits were at 0, 3, 6 and 12 months. Bleeding patterns were recorded by the patient in a diary and clinical compliance was evaluated at control visits during the treatment. Symptoms were recorded using a modified Kuppermann index. The serum estradiol concentration was determined at the 0, 6 and 12 month control visits. Results: 80% (n = 16) of the patients in the LNG-IUD group, 67% (n = 14) in the oral P group II and 53% (n = 10) in the vaginal P group were without bleeding at 12 months. Spotting was common during the first 3 months. Symptom relief was good in each group. The LNG-IUD did not cause any serious side-effects. Compliance was good for LNG-IUD and oral progesterone but not for vaginal progesterone. Conclusions: Percutaneous estradiol-gel associated with LNG-IUD is an appropriate method of hormone replacement therapy. The combination of oral natural progesterone with estradiol-gel is also useful, although bleeding episodes complicated the treatment in one third of the patients. The vaginal administration of natural progesterone was impractical due to bleeding disorders.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 009170573

Download citation: RISBibTeXText

PMID: 9147353

DOI: 10.1016/s0378-5122(96)01100-0


Related references

Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone. Acta Obstetricia Et Gynecologica Scandinavica. 77(7): 758-763,., 1998

Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. American Journal of Obstetrics & Gynecology 172(2 Part 1): 562-567, 1995

Lipid effects of an intrauterine levonorgestrel device or oral vs. vaginal natural progesterone in post-menopausal women treated with percutaneous estradiol. Archives of Gynecology and Obstetrics 261(4): 201-208, 1998

Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: Clinical and endometrial responses. Maturitas 26(2): 103-111, 1997

Three-year follow-up of the use of a levonorgestrel-releasing intrauterine system in hormone replacement therapy. Acta Obstetricia et Gynecologica Scandinavica 76(2): 145-150, 1997

One year follow-up of hormone replacement therapy with percutaneous estradiol and low-dose vaginal natural progesterone in women with mild to moderate hypertension. Experimental and Clinical Endocrinology and Diabetes 111(5): 267-273, 2003

Effect of the levonorgestrel-releasing intrauterine system on the uterine artery pulsatility index in postmenopausal hormone replacement therapy. Ultrasound in Obstetrics and Gynecology 10(5): 350-355, 1997

The effect of a levonorgestrel-releasing intrauterine device on human endometrial oestrogen and progesterone receptors after one year of use. Human Reproduction 14(4): 970-975, 1999

Estradiol/progesterone-releasing vaginal rings for hormone replacement therapy in postmenopausal women. Gynecological Endocrinology 17(3): 247-254, 2003

Insulin sensitivity during postmenopausal hormone replacement with transdermal estradiol and intrauterine levonorgestrel. Acta Obstetricia et Gynecologica Scandinavica 78(6): 540-545, 1999

Amenorrhea during hormone replacement therapy by the association of percutaneous 17-beta-estradiol and oral micronized progesterone. Contraception Fertilite Sexualite 21(11): 849-852, 1993

Amenorrhea during menopausal hormone replacement therapy with a percutaneous estradiol and oral micronized progesterone combination. Contraception Fertilite Sexualite 21(11): 849-852, 1993

The endometrium under the effects of hormone replacement therapy in menopause with percutaneous estradiol and low-dose micronized progesterone. Pathologica 85(1099): 475-487, 1993

The effect of levonorgestrel-releasing intrauterine device on menorrhagia in women taking anticoagulant medication after cardiac valve replacement. Contraception 80(2): 152-157, 2009